News Snapshot:
A nurse attends to a patient suffering from COVID-19 at a hospital in Spain. © Reuters KENYA AKAMA, Nikkei staff writer April 7, 2021 00:22 JST | Japan Copy Copied TOKYO -- Takeda Pharmaceutical has suspended the development of a plasma therapy for COVID-19 after it failed to show effectiveness in clinical trials, according to a Tuesday disclosure to investors. Japan's top drugmaker, along with U.S.-based CSL Behring and other members of the CoVIg-19 Plasma Alliance, had been working on a new treatment for the coronavirus using antibodies taken from the plasma of recovered patients. Roughly 600 patients in 10...
